These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 26497109

  • 1. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
    Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Kasahara K.
    Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 3. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D, Andersen L, Forth R, Jacques L, Yates L.
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [Abstract] [Full Text] [Related]

  • 4. A Comparison of the Efficacy of Once-Daily Fluticasone Furoate/Vilanterole with Twice-Daily Fluticasone Propionate/Salmeterol in Elderly Asthmatics.
    Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Abo M, Kasahara K.
    Drug Res (Stuttg); 2018 Jan; 68(1):38-44. PubMed ID: 28926855
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C.
    Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
    Adachi M, Goldfrad C, Jacques L, Nishimura Y.
    Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
    [Abstract] [Full Text] [Related]

  • 7. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 8. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
    Hozawa S, Terada M, Haruta Y, Hozawa M.
    Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial.
    Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin JM.
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [Abstract] [Full Text] [Related]

  • 10. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A.
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [Abstract] [Full Text] [Related]

  • 11. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J, Kang J, Lee SH, Wang C, Zhou X, Crawford J, Jacques L, Stone S.
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [Abstract] [Full Text] [Related]

  • 12. Effect of triple therapy in patients with asthma-COPD overlap
.
    Ishiura Y, Fujimura M, Ohkura N, Hara J, Kasahara K, Ishii N, Tamaki T, Shimizu T, Nomura S.
    Int J Clin Pharmacol Ther; 2019 Aug; 57(8):384-392. PubMed ID: 31232275
    [Abstract] [Full Text] [Related]

  • 13. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.
    Respir Res; 2015 Feb 15; 16(1):25. PubMed ID: 25849223
    [Abstract] [Full Text] [Related]

  • 14. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb 15; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID.
    Lancet Respir Med; 2021 Jan 15; 9(1):69-84. PubMed ID: 32918892
    [Abstract] [Full Text] [Related]

  • 16. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER, Lötvall J, O'Byrne PM, Woodcock A, Busse WW, Kerwin EM, Forth R, Medley HV, Nunn C, Jacques L, Bateman ED.
    J Allergy Clin Immunol Pract; 2014 Jan 15; 2(5):553-61. PubMed ID: 25213048
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep 15; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 18. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr 15; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.
    Woodcock A, Bleecker ER, Lötvall J, O'Byrne PM, Bateman ED, Medley H, Ellsworth A, Jacques L, Busse WW.
    Chest; 2013 Oct 15; 144(4):1222-1229. PubMed ID: 23846316
    [Abstract] [Full Text] [Related]

  • 20. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr 15; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.